<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337829</url>
  </required_header>
  <id_info>
    <org_study_id>15-H-0016</org_study_id>
    <nct_id>NCT02337829</nct_id>
  </id_info>
  <brief_title>Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL</brief_title>
  <official_title>A Phase II Study Using ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the response to acalabrutinib in patients with chronic lymphocytic
      leukemia (CLL) or small lymphocytic lymphoma (SLL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the safety and efficacy of acalabrutinib for patients with CLL/SLL that have
      relapsed/refractory disease or treatment naive deletion 17p.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response based on overall response rate</measure>
    <time_frame>Cycle 1 (28 Days) to 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>to undergo superficial lymph node biopsies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>to undergo bone marrow biopsies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acalabrutinib</intervention_name>
    <description>Patients undergo lymph node biopsies</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>ACP-196</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acalabrutinib</intervention_name>
    <description>Patients undergo bone marrow biopsies</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>ACP-196</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18 years of age and older with histologically confirmed disease.

          -  Active disease as defined by at least one of the following (IWCLL consensus criteria):

               -  Weight loss ≥10% within the previous 6 months

               -  Extreme fatigue

               -  Fevers of greater than 100.5ºF for ≥2 weeks without evidence of infection

               -  Night sweats for more than one month without evidence of infection

               -  Evidence of progressive marrow failure as manifested by the development of, or
                  worsening of, anemia and/or thrombocytopenia

               -  Massive or progressive splenomegaly

               -  Massive nodes or clusters or progressive lymphadenopathy

               -  Progressive lymphocytosis with an increase of &gt;50% over a 2 month period, or an
                  anticipated doubling time of less than 6 months

               -  Compensated autoimmune hemolysis

          -  Relapsed/Refractory CLL/SLL or treatment naïve patients

          -  Agreement to use acceptable methods of contraception during the study and for 30 days
             after the last dose of study drug if sexually active and able to bear or beget
             children.

          -  Willing and able to participate in all required evaluations and procedures in this
             study protocol including swallowing capsules without difficulty and serial biopsies.

          -  Ability to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use protected health information (in accordance
             with national and local subject privacy regulations).

        Exclusion Criteria:

          -  Radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or investigational
             products in the last 4 weeks.

          -  Richter's transformation. Autoimmune hemolytic anemia or thrombocytopenia requiring
             steroid therapy. Impaired hepatic function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Penn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acerta Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tasheda Navarro</last_name>
    <phone>650 670 5439</phone>
    <email>t.navarro@acerta-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>301-827-1094</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>Btk</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Small Lymphocytic Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphocytic</keyword>
  <keyword>ACP-196</keyword>
  <keyword>acalabrutinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

